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e MMP enzyme treatment shifts the liposomes surface charge  from negative 
to positive due to removal of PEG and the four glutamic acid residues.
Incorporation of PCL makes the liposomes responsive to enzyme environment 
and provides them with a charge switch that controls their interaction with cells 
and thereby the drug delivery.
PCL is cleaved by MMP which is overexpressed in the brain under inammatory 
conditions. e delivery system is thereby optimized for drug delivery fallowing 
stroke and will be tested in stroke models. We are now implementing novel single 
liposome characterization assays to facilitate a deeper mechanistic understanding 
and provide new insights for optimizing the drug delivery system, potentially al-
lowing us to create membrane fusiogenic liposomes.
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Conclusion and Perspectives
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Concept
e liposome contains a PEGylated cleavable lipo-
peptide (PCL) which makes it responsive to matrix 
metalloprotease (MMP). 
e PCL sequence contains four glutamic acid resi-
dues which provide the negative charge.
High MMP activity triggers the cleavage of PCL 
and thereby exposure of a concealed positive charge 
in the form of three arginine residues (R3) anchored 
by cholesterol. e exposure of R3 increases cell in-
teraction and drug delivery.
In the future we hope to create a charge mediated 
fusiogenic liposome system, inspired by the vary ef-
cient delivery mechanism employed by viruses.
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e shift in surface charge facilitates interaction with the negatively charged cell 
membrane leading to increased uptake of MMP enzyme treated liposomes in 
HT1080 cells after 3 h incubation.
Enzymatic responsive uptake
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Single Liposome characterization
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Dye/Drug Channel
120
100
80
60
40
20
0
N
um
be
r o
f L
ip
os
om
es
5004003002001000
Diameter
# of liposomes = 1953
per frame = 326
8
6
4
2
0P
er
ce
nt
ag
e 
of
 L
ip
os
om
es
1000080006000400020000
Conc a.u.
Single liposome assay for characterization of heterogeneities in the phys-
io-chemical properties of individual liposomes. Here is presented prelimenary 
results for size and drug concentration of single liposomes. 
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